Physiologically-Based Pharmacokinetic Modeling & Simulation to Support Asciminib NDA Submission & Inform Drug Product Label
Physiologically based pharmacokinetic (PBPK) modeling and simulation has become an established approach to assess drug-drug…
CertaraJanuary 13, 2023
New FDA Validator Rules V1.6 Explained
In this blog, we explore what you need to know about the update to the…
CertaraJanuary 12, 2023
Simcyp Secondary Intelligence Software
Introducing Secondary Intelligence. The first and only evidence based quantitative technology for managing off target…
CertaraJanuary 10, 2023
Certara Awarded NIH Contract for Toxicology Consulting Support
Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system…
CertaraJanuary 10, 2023
Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme
PRINCETON, N.J., January 9, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,…
CertaraJanuary 9, 2023
Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
Certara improves software capabilities by expanding into deep learning and data fabric PRINCETON, N.J.— January…
CertaraJanuary 4, 2023
New FDA Requirement to Support Labeling on DDIs in the Pediatric Population
The effects of drug-drug interactions (DDIs) could differ in the pediatric population compared to adults.…
CertaraDecember 21, 2022
